Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference GlobeNewswire June 04, 2025 WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025 at 10:40 a.m. ET. […]
Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis GlobeNewswire June 04, 2025 SION-719 and SION-451 were generally well tolerated and achieved desired pharmacokinetic targets that reinforce their potential as either an add-on to standard of care or in a Sionna
NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor NT-0796 GlobeNewswire June 04, 2025 NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor NT-0796 Pioneering small-molecule program, NT-0796, targets chronic inflammation and its fundamental role in the
Bitget Partners with University of Zurich Blockchain Center, Providing Opportunities and Scholarships for Students GlobeNewswire June 04, 2025 VICTORIA, Seychelles, June 04, 2025 (GLOBE NEWSWIRE) — Bitget, the leading cryptocurrency exchange and Web3 company, has announced a partnership with the University of Zurich, the world's top #3 university (according to Coindesk's 2021/22 rankings) for blockchain
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2 GlobeNewswire June 04, 2025 Initial Data from the Ongoing, Blinded Phase 1 Single-Ascending Dose Trial Has Demonstrated Favorable Safety and Pharmacokinetics IND Application Submitted to Expand RESTORE-FA Trial to U.S. Sites; Notice Received from FDA
Eldorado Gold Announces Election of Directors and Results from the 2025 Annual and Special Meeting of Shareholders GlobeNewswire June 04, 2025 VANCOUVER, British Columbia, June 04, 2025 (GLOBE NEWSWIRE) — Eldorado Gold Corporation (“Eldorado” or “the Company”) is pleased to announce that all director nominees, as listed in the Management Proxy Circular dated April 15,
Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards(R) GlobeNewswire June 04, 2025 Gold-level Stevie(R) Award recognizes Maetzold's transformative leadership in the healthcare industry, including molecular diagnostics and precision medicine FRIENDSWOOD, Texas, June 04, 2025 (GLOBE NEWSWIRE) — Castle Biosciences, Inc. (Nasdaq: CSTL), a company
(NYSE:BAM),(TSX:BAM),(TSX:BAM.TO),(NYSE:BAM), NEW YORK and STOCKHOLM, June 04, 2025 (GLOBE NEWSWIRE) — Brookfield Asset Management (“Brookfield”) today announced up to SEK 95 billion ($10 billion) of investment to support the development of artificial intelligence (“AI”) infrastructure in Sweden. This investment represents one of Brookfield's largest AI investments in Europe and extends the partnership with the Swedish
(CNSX:RVV.CN),(CNSX:RVV),(OTC US:RVVTF),(Other OTC:RVVTF),(Frankfurt:31R), TORONTO, June 04, 2025 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, is pleased to announce the advancement of its next-generation lyophilized formulation of Bucillamine (“New Bucillamine”). Developed in collaboration
(NYSE Arca:XYZY),(NYSE Arca:WNTR),(NYSE Arca:SMCY),(NYSE Arca:AIYY),(NYSE Arca:MSTY), CHICAGO and MILWAUKEE and NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) — YieldMax(R) today announced distributions for the YieldMax(R) Weekly Payers and Group D ETFs listed in the table below. ETF Ticker1 ETF Name Distribution Frequency Distribution per Share Distribution Rate2,4 30-DaySEC Yield3 ROC5 Ex-Date & Record Date Payment Date